Navigation Links
Athera Receives Allowance of Two Key Patents

STOCKHOLM, October 14 /PRNewswire/ -- Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual property on its two pharmaceutical candidates Annexin A5 and PC-mAb.

Following subsequent grant the patents will be registered in the designated European countries, and there are corresponding patent applications pending worldwide. Together, the patents will provide strong protection for pharmaceutical uses of Annexin A5 for the prevention of plaque rupture, as well as use of PC-mAb for the treatment of atherosclerosis and prevention of ischemic cardiovascular disease.

"These European patents strengthens our efforts in building an attractive and competitive pharmaceutical product portfolio in cardiovascular disease," said Carina Schmidt, Athera Biotechnologies Chief Executive Officer. "I am convinced that the product candidates that Athera develops have the potential to fulfil important medical needs. We can see this also in a great interest from the pharmaceutical industry to explore partnering opportunities with Athera for future clinical developments."

Natural antibodies to phosphorylcholine (PC) are known to be cardio-protective and are antibodies to specific surface regions on OxLDL. High levels of antibodies against PC (anti-PC) have been shown to be predictive of less atherosclerosis development in hypertensive patients. Later data from several studies confirm that low anti-PC levels predict an increased risk of CVD and even are linked to increased mortality in Acute Coronary Syndrome patients. The pharmaceutical product candidate, PC-mAb, is developed by Athera in collaboration with Dyax Corp. in Boston, USA (NASDAQ:DYAX). The biomarker product CVDefine(R), that has the potential to enable a "theranostics" approach in prevention of cardiovascular disease, is on the market and provides an easy-to-use ELISA kit (CE-marked) for quantitative analysis of anti-PC in human blood.

Athera's second novel product candidate, Annexin A5, is developed for prevention of plaque rupture and athero-thrombosis through binding of the protein to endothelium. The recombinant protein Annexin A5 is intended for the treatment of patients with Acute Coronary Syndrome and who are at imminent risk for Myocardial Infarction. Athera has an agreement with Richter-Helm BioLogics GmbH & Co. KG in Hamburg, Germany, for the process development of the product.

About Athera Biotechnologies

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera is a Karolinska Development AB (publ) portfolio company and is also a major partner in the highly ranked EU-project CVDIMMUNE, which also includes Karolinska Institute, Imperial College London, Phadia GmbH and TNO.


Carina Schmidt, CEO Phone: +46-70-552-5115, Mail:

SOURCE Athera Biotechnologies AB

SOURCE Athera Biotechnologies AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
2. Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
3. Athera Signs Agreements With German and UK Distributors for New Cardiovascular Biomarker
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. IsoTis Receives FDA Clearance for Accell Family of Products
9. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Post Your Comments:
(Date:12/1/2015)... OXFORD, England , December 1, 2015 ... Touch is a touch activated lancet that features Owen ... Vancouver , booth 1403, Unistik® Touch is a ... Zone Technology®. --> Owen Mumford, a leading ... its range of medical devices, available initially in the ...
(Date:12/1/2015)... SEATTLE , Dec. 1, 2015 Today ... headquarters in Seattle,s South Lake ... northwest corner of Mercer Street and Westlake Avenue North, ... to the Allen Institute for Brain Science and the ... Allen , philanthropist and founder of the Allen Institute. ...
(Date:12/1/2015)... -- Researchers at the Broad Institute of MIT and ... MIT have engineered changes to the revolutionary CRISPR-Cas9 genome ... errors. The refined technique addresses one of the major ... Science , Feng Zhang and his ... amino acids that make up the Cas9 enzyme from ...
(Date:12/1/2015)... Dec. 1, 2015  Twist Bioscience, a company focused on ... , Ph.D., has been selected as one of Foreign ... fast-tracking the building blocks of life . Each year, ... whose contributions and work have changed lives and are shaping ... "It is an honor to be recognized among these incredible ...
Breaking Biology Technology:
(Date:12/1/2015)... JOSE, Calif. , Dec. 1, 2015 ... of human interface solutions, today announced a new agreement ... enable OEMs with real-world test and development environments that ... Labs solutions. The partnership reduces the complexity of FIDO ... and software permits Synaptics and OEMs to verify FIDO ...
(Date:11/30/2015)... DEERFIELD BEACH, Fla. , Nov. 30, 2015 ... selected as a finalist in this year,s Fierce Innovation ... publisher of FierceHealthIT , ... BIOCLAIM was recognized as a finalist in the ... --> ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Capacitive Fingerprint Sensors - Technology and ... --> --> ... market, especially in smartphones. The fingerprint sensor vendor Idex ... fingerprint sensor units in mobile devices and of the ...
Breaking Biology News(10 mins):